Medical isotope firm Shine Medical Technologies made its first commercial sales of its lutetium-177 (Lu-177) therapeutic isotope to multiple customers.
Numerous clinical trials are underway for Lu-177, a low-energy beta-particle emitter that works by directly irradiating cancer cells after they are delivered to a cancer site by a targeting molecule. Lu-177 is used to treat neuroendocrine cancers.
Currently, Shine is producing the isotope at a small building on its campus. Groundbreaking for a larger facility, which will be capable of producing more than 300,000 doses of Lu-177 per year, is expected in November.
